Revance Therapeutics Inc (NAS:RVNC)
$ 3.04 -0.02 (-0.65%) Market Cap: 317.35 Mil Enterprise Value: 618.80 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Q2 2021 Revance Therapeutics Inc Earnings Call Transcript

Aug 05, 2021 / 08:30PM GMT
Release Date Price: $29.83 (+1.74%)
Operator

Good day, everyone. Welcome to Revance Therapeutics Second Quarter 2021 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, August 5, 2021.

I would now like to turn the conference over to Jessica Serra, Head of Investor Relations and ESG for Revance. Please go ahead.

Jessica Serra
Revance Therapeutics, Inc. - Head of IR & ESG

Joining us on the call today from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Tobin Schilke; Chief Operating Officer and President of R&D and Product Operations,Dr. Abhay Joshi; Chief Commercial Officer, Aesthetics and Therapeutics, Dustin Sjuts; and President of Innovation and Technology, Aubrey Rankin.

During this conference call, management will make forward-looking statements including statements related to the clinical development of our product candidates, our business strategy, planned operations, commercialization plans, potential benefits of our drug product candidates and technology,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot